Free. Simple. Effective. Over 50,000 Cases Processed! |
|
| Paxil |
| | 108 | 2008-03-16 |
|
| Paxil, as well as other SSRIs, has been linked to Persistant Pulmonary Hypertension in the Newborn (PPHN) - a devastating condition affecting the heart and lungs of newborn infants. Babies are unable to breath properly due to constricted blood vessels which cut off oxygen to the blood and cause damage to other organs such as brain and kidneys. Even babies that receive treatment may not recover, and those that do may have long-term breathing problems. Paxil is used by millions of people worldwide and generates more than $1 billion in annual sales. Paxil has been in the news previously for complaints of severe withdrawal symptoms and risks of suicidal behavior and increased violence in children and adolescents. Paxil is known as a Selective Serotonin Reuptake Inhibitor (SSRI). The FDA warns physicians to carefully weigh the potential risks and benefits of prescribing or renewing Paxil prescriptions to women during pregnancy or while breast-feeding. It is important that all patients are aware of the side effects, risks, and treatment alternatives. Paxil Birth Defects, PPHN and Infant Death On September 27, 2005, the FDA issued an alert to healthcare professionals and consumers as GlaxoSmithKline changed their warning label on Paxil (paroxetine) to include the risk of birth defects. The results of a recent study conducted by the two indicated an increased risk of babies born with birth defects, specifically cardiovascular defects or congenital malformations, in instances where the mother was taking Paxil during the first trimester of pregnancy. |
|
|
|
|